

## Review Article

# Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada

George G. Zhanel , Michael A. Zhanel, and James A. Karlowsky 

Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada

Correspondence should be addressed to George G. Zhanel; ggzhanel@pcs.mb.ca

Received 17 January 2018; Revised 26 April 2018; Accepted 17 May 2018; Published 25 June 2018

Academic Editor: José A. Oteo

Copyright © 2018 George G. Zhanel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fosfomycin is a bactericidal agent that inhibits cell wall synthesis using a mechanism of action distinct from  $\beta$ -lactams or other antimicrobial agents. It is a broad-spectrum agent that is frequently active against antimicrobial-resistant bacterial pathogens including methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), multidrug-resistant (MDR) Enterobacteriaceae, and some isolates of MDR *Pseudomonas aeruginosa*. Intravenous fosfomycin has been prescribed for a wide variety of infections in many countries for >40 years. It is most frequently used in combination with other antimicrobial agents (e.g.,  $\beta$ -lactams, carbapenems, and aminoglycosides) and has an excellent safety profile, including in neonates and children, even with long-term administration (weeks). Fosfomycin achieves extensive tissue distribution including difficult to reach compartments such as aqueous humor, vitreous humor, abscess fluid, and CSF. Available data, to date, suggest no clinically relevant pharmacological interactions between fosfomycin and other agents, including drugs, stimulants, or food. Intravenous fosfomycin's role in therapy in Canada is likely as an agent used alone or in combination for complicated urinary tract infections in hospitalized patients as well as hospitalized patients with MDR infections who have not responded to first-, and potentially, second-line antimicrobials or in patients who cannot tolerate (due to adverse effects) first- and second-line antimicrobials.

## 1. Current State of Antimicrobial-Resistant Infections in Canada

*1.1. Context: Global Trends in Antimicrobial Resistance.* Infections among hospitalized patients in Canada, and worldwide, are increasingly reported to be attributable to antimicrobial-resistant, multidrug-resistant (MDR), and extensively drug-resistant (XDR) bacterial pathogens [1–6]. These pathogens include, but are not limited to, methicillin-resistant *Staphylococcus aureus* (MRSA), both community-associated MRSA (CA-MRSA) and healthcare-associated MRSA (HA-MRSA), vancomycin-resistant enterococci (VRE), penicillin-resistant *Streptococcus pneumoniae*, extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae*, fluoroquinolone-resistant and carbapenem-resistant Enterobacteriaceae (CRE), MDR *Pseudomonas aeruginosa*, and MDR *Acinetobacter* spp. [1–6]. Treatment options for antimicrobial-resistant, MDR, and

XDR bacterial pathogens can be limited. Therefore, ongoing development of new agents, ideally with novel, bactericidal mechanisms of action and reliable activity against antimicrobial-resistant bacterial pathogens, is essential. Strong antimicrobial stewardship programs are also vital to curbing the emergence and spread of antimicrobial-resistant pathogens and to the future of successful infectious diseases patient care.

*1.2. The CANWARD Surveillance Study: An Annually Trended and Current Perspective on Antimicrobial Resistance in Canadian Hospitals.* For more than a decade, the Canadian Antimicrobial Resistance Alliance-CARA/Health Canada partnered CANWARD surveillance study has reported on the prevalence of antimicrobial-resistant bacterial pathogens in Canadian tertiary care hospitals. CANWARD annually collects clinical isolates from a network of participating laboratories across Canada and performs standardized

TABLE 1: The 20 most common bacterial pathogens isolated from patient samples in Canadian hospitals, CANWARD surveillance study, 2007–2016.

Rank	Organism	Number of isolates	% of total isolates
1	<i>Escherichia coli</i>	8,387	19.5
2	<i>Staphylococcus aureus</i> , MSSA	7,146	16.6
3	<i>Pseudomonas aeruginosa</i>	3,864	9.0
4	<i>Streptococcus pneumoniae</i>	2,626	6.1
5	<i>Klebsiella pneumoniae</i>	2,624	6.1
6	<i>Staphylococcus aureus</i> , MRSA	1,963	4.6
7	<i>Haemophilus influenzae</i>	1,764	4.1
8	Coagulase-negative staphylococci/ <i>Staphylococcus epidermidis</i>	1,616	3.8
9	<i>Enterococcus faecalis</i>	1,255	2.9
10	<i>Enterobacter cloacae</i>	1,060	2.5
11	<i>Streptococcus agalactiae</i>	689	1.6
12	<i>Stenotrophomonas maltophilia</i>	669	1.6
13	<i>Klebsiella oxytoca</i>	668	1.6
14	<i>Proteus mirabilis</i>	647	1.5
15	<i>Serratia marcescens</i>	647	1.5
16	<i>Streptococcus pyogenes</i>	642	1.5
17	<i>Enterococcus</i> , nonsp. spec.	582	1.4
18	<i>Enterococcus faecium</i>	481	1.1
19	<i>Candida albicans</i>	478	1.1
20	<i>Moraxella catarrhalis</i>	468	1.1
	Others	4,729	11.0
Total		42,938	

Adapted from [6].

Clinical and Laboratory Standards Institute (CLSI) defined broth microdilution antimicrobial susceptibility testing on the isolates in a central (coordinating) clinical microbiology laboratory [6–9]. From 2007 to 2016, CANWARD determined the in vitro activities (e.g., MIC<sub>50</sub>, MIC<sub>90</sub>, and MIC range) of dozens of marketed antimicrobials against ~43,000 clinical isolates from blood (43.5% of isolates), respiratory (33.1%), urine (13.2%), and wound (10.2%) specimens [6]. Patient demographic parameters associated with these isolates included the following: patient's gender: male (54.6% of isolates) and female (45.4%); patient age: ≤17 years (13.0%), 18–64 years (44.3%), and ≥65 years (42.7%); and patient location: medical and surgical wards (38.1%), emergency rooms (24.8%), clinics (18.1%), and intensive care units (19.0%).

The CANWARD surveillance study has determined that the most common bacterial pathogens isolated from patients attending Canadian tertiary care hospitals (due to community acquired or healthcare-acquired infections) over the last decade (2007–2016) were *S. aureus* (21.2%), includes both methicillin-susceptible *S. aureus* (MSSA) and methicillin-resistant *S. aureus* (MRSA), *E. coli* (19.5%), *P. aeruginosa* (9.0%), *S. pneumoniae* (6.1%), *K. pneumoniae* (6.1%), *Enterococcus* spp. (5.4%), *Haemophilus influenzae* (4.1%), and coagulase-negative staphylococci (3.8%) (Table 1) [6].

Antimicrobial susceptibility rates among Gram-positive cocci identified in CANWARD from 2007 to 2016 were highest for linezolid, daptomycin, and vancomycin, whereas for Gram-negative bacilli, susceptibility rates were highest for colistin, tigecycline, amikacin, ceftolozane-tazobactam, and meropenem [6, 7]. Among the most common pathogens, MRSA susceptibility rates were 100% for linezolid, 99.9% for vancomycin and daptomycin, 99.2% for tigecycline, 97.5% for

doxycycline, 94.1% for trimethoprim-sulfamethoxazole, and 53.9% for clindamycin. *Streptococcus pneumoniae* susceptibility rates were 100% for vancomycin, 99.4% for ceftriaxone, 99.1% for moxifloxacin, 86.7% for doxycycline, 82.6% for penicillin, and 78.4% for clarithromycin. The most active agents against *E. coli* were meropenem, imipenem, and tigecycline (all >99.9% susceptible); colistin (99.8% using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC breakpoint); ertapenem and amikacin (both 99.7%); ceftolozane-tazobactam and piperacillin-tazobactam (both 97.6%); cefepime (95.1%); for ceftazidime (93.7%); ceftriaxone (91.8%); gentamicin (90.5%); for ciprofloxacin (77.9%); and trimethoprim-sulfamethoxazole (73.2%) [6]. Similarly, *P. aeruginosa* antimicrobial susceptibility rates for the most active agents in vitro were 98.3% for ceftolozane-tazobactam, 95.0% for colistin, 92.0% for amikacin, 84.2% for piperacillin-tazobactam, 82.9% for ceftazidime, 81.2% for meropenem, 79.7% for gentamicin, and 75.4% for ciprofloxacin [6]. For *Acinetobacter baumannii*, antimicrobial susceptibility rates for the most active agents in vitro were 97.5 for colistin, 95.9% for amikacin, 94.7% for meropenem, and 92.4% for ciprofloxacin [6, 7].

**1.3. MRSA in Canada.** For MRSA, CANWARD has documented a significant decrease in prevalence (% MRSA among *S. aureus*) from 26.1% in 2007 to 19.3% in 2011, with 28.9% of MRSA being community-associated CA-MRSA genotypes and 68.6% healthcare-associated HA-MRSA genotypes [10]. The prevalence of CA-MRSA genotypes significantly increased from 19.7% to 36.4% between 2007 and 2011 ( $P < 0.0001$ ), with CA-MRSA10 (USA300) being the

predominant CA-MRSA genotype. The hVISA phenotype was detected in 7/27 (25.9%) isolates of MRSA with a vancomycin MIC of 2 µg/mL [10].

**1.4. VRE in Canada.** For VRE, CANWARD reported a Canadian prevalence of 4.2% (80/1927), with a significant increase from 1.8% in 2007 to 6.0% in 2013 [11]. All 80 VRE isolates were identified as *E. faecium*, with 90% carrying the *vanA* gene and 10% the *vanB* gene. All VRE were resistant to ciprofloxacin, levofloxacin, and vancomycin; 70.6%, 86.3%, and 100% of VRE were susceptible to doxycycline, linezolid, and daptomycin, respectively [11]. Treatment options for infections caused by VRE are currently limited.

**1.5. ESBL-Producing *E. coli* and *K. pneumoniae* in Canada.** In CANWARD, the prevalence of ESBL-producing *E. coli* and *K. pneumoniae* increased significantly from 3.4% to 12.6% and from 1.5% to 6.7%, respectively, from 2007 to 2016 [8, 9]. Approximately 31% of ESBL-producing *E. coli* displayed an MDR phenotype with concomitant resistance to cephalosporins, fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole [8]; 0.8% of ESBL-producing *E. coli* were XDR (defined as concomitant resistance to ≥5 different antimicrobial classes). The majority of ESBL-producing *E. coli* in Canada, and elsewhere, are clonal (ST131) and carry the ESBL gene, CTX-M-15; the spread of the ST131 clone is also responsible for the majority of the observed increase in fluoroquinolone resistance among ESBL-producing *E. coli* over the last decade [8]. The most active agents against ESBL-producing *E. coli* were colistin, meropenem, and tigecycline (all >99.9% susceptible) along with ertapenem, amikacin, and ceftolozane-tazobactam (all ~98% susceptible) [6, 7, 9, 10]. CANWARD has also recently identified the appearance of and slow increases in carbapenem resistance among clinical isolates of *E. coli* and *K. pneumoniae* (e.g., KPC-3) [8, 9].

**1.6. MDR *P. aeruginosa* in Canada.** MDR isolates of *P. aeruginosa* (i.e., concomitant resistance to ≥3 different antimicrobial classes) currently account for 5–10% of isolates of *P. aeruginosa* in CANWARD and demonstrate reduced susceptibility to many antipseudomonal agents, including tobramycin (92.6% susceptible (for all isolates) versus 51.3% susceptible (for MDR isolates)), piperacillin-tazobactam (85.1% versus 18.4%), meropenem (83.5% versus 16.5%), ciprofloxacin (77.9% versus 13.4%), and ceftazidime (83.7% versus 11.4%); in contrast, colistin is equally active against all isolates of *P. aeruginosa* and against MDR subsets (97.5% versus 98.1%) [12]. Ceftolozane/tazobactam displayed 99.0% susceptibility against all isolates of *P. aeruginosa* and 89.2% against MDR isolates [12].

## 2. Current Need for New Antimicrobial Agents in Canada

**2.1. Need for New Antimicrobial Agents for Infections Caused by Resistant Gram-Positive Cocci.** The most urgent need for new antimicrobials for Gram-positive pathogens in Canada is

to address infections such as respiratory, bacteremic (including endocarditis), complicated skin and skin structure infections, and bone and joint infections that are associated with *S. aureus*, and specifically, infections caused by MRSA. *S. aureus* (both MRSA and MSSA) rank first among the most common pathogens in Canadian hospitals (Table 1), and MRSA represents ~20% of all *S. aureus* isolates. Systemic MRSA infections in the hospital setting are currently treated with vancomycin; however, poor treatment outcomes, concern about the development of hVISA, MIC creep, pharmacokinetic limitations regarding certain compartments such as the central nervous system, and high rates of nephrotoxicity with increasing doses of vancomycin (to maintain serum trough levels at 15–25 µg/mL and/or AUC >400 µg·hr/mL) have clinicians reassessing vancomycin's role. Linezolid is active in vitro but is a bacteriostatic agent and is accompanied by hematological toxicities with prolonged use and drug interactions, whereas daptomycin cannot be used for MRSA respiratory infections due to inactivation by lung surfactant.

There is also an urgent need for new antimicrobials in Canada to address urinary tract, bacteremic, and wound infections associated with *Enterococcus* spp., especially VRE. *Enterococcus* spp. (*E. faecalis*, *E. faecium*, and unspecified *Enterococcus* spp. grouped together) accounted for 5.4% of bacterial pathogens isolated by CANWARD from 2007 to 2016 (Table 1), making it the sixth most common pathogen in Canadian hospitals with VRE accounting for ~6% of all *Enterococcus* spp. VRE are also commonly MDR with only linezolid and daptomycin as potential options for systemic infections. Linezolid, as mentioned earlier, is bacteriostatic; increasingly, isolates of VRE are intermediately resistant to linezolid and are associated with hematological toxicities with prolonged use. Daptomycin displays elevated MICs against some *Enterococcus* spp. and dosing (mg/kg) can be unclear.

**2.2. Need for New Antimicrobial Agents for Infections Caused by Resistant Gram-Negative Bacilli.** *E. coli*, *K. pneumoniae*, and *P. aeruginosa* are the most common Gram-negative bacilli causing infections in Canadian hospitals (Table 1) and are frequently MDR and are increasingly XDR. Growingly, ESBL-producing *E. coli* and *K. pneumoniae* are becoming resistant to carbapenems and isolates of carbapenem-resistant Enterobacteriaceae (CRE) are expected to increase in prevalence over time. The most immediate need for new antimicrobials to treat infections caused by Gram-negative pathogens in Canada is for infections such as urinary, respiratory, bacteremia (including endocarditis), intra-abdominal, and complicated skin and skin structure infections associated with ESBL-producing *E. coli* and *K. pneumoniae*, CRE, and MDR *P. aeruginosa*. The frequent and serious nature of neurotoxicity and nephrotoxicity with colistin, nephrotoxicity and ototoxicity with aminoglycosides, and increased mortality associated with tigecycline precludes their use unless absolutely necessary. *P. aeruginosa* is a nosocomial pathogen that is intrinsically resistant to many antimicrobial agents, frequently develops resistance on therapy, and is a concern because up to 10% of isolates are MDR, leaving only aminoglycosides (e.g., amikacin and tobramycin),




FIGURE 1: Chemical structures of fosfomycin.

colistin, and ceftolozane-tazobactam as therapies of last resort. Although ceftolozane/tazobactam is active against most MDR *P. aeruginosa*, new agents are needed, whether to be used alone or in combination with existing agents. Aminoglycosides, as mentioned earlier, are well-described nephrotoxins and ototoxicity, require therapeutic drug monitoring, have poor activity at low pH, and demonstrate poor penetration into lung tissue, whereas colistin is a well-described neurotoxin and nephrotoxin. The risk/benefit ratio of using these either of these two agents is poor.

**2.3. Ideal Properties of New Antimicrobial Agents.** An ideal new antimicrobial agent for treating systemic infections in patients in Canadian hospitals would have a proven track record of bacteriological and clinical efficacy, an excellent safety profile, and outstanding pharmacokinetic (i.e., extensive tissue distribution including urine, bone, and cerebrospinal fluid (CSF)) and pharmacodynamics properties. The agent would be available as an intravenous therapy and possess a new mechanism of action with bactericidal activity against bacterial pathogens resistant to other antimicrobial classes (e.g., penicillins, cephalosporins,  $\beta$ -lactams/ $\beta$ -lactamase inhibitor combinations, carbapenems, fluoroquinolones, sulfonamides, and aminoglycosides). The agent would be associated with limited resistance development during treatment, would be available to be used alone or in combination with other antimicrobials, and would demonstrate additive or synergistic efficacy when used in combination with other agents.

### 3. Fosfomycin: Structure, Mechanism of Action, and Pharmacokinetic/ Pharmacodynamic Properties

The chemical structure of fosfomycin is *cis*-1,2-epoxypropyl phosphonic acid ( $C_3H_7O_4P$ ; molecular mass, 138.1 g/mol) and is depicted in Figure 1. The epoxide moiety is the principal structural determinant conferring fosfomycin's antibacterial activity. Fosfomycin was originally described in 1969, a result of screening broth cultures of soil containing *Streptomyces fradiae*. Today, fosfomycin is produced synthetically using phosphonic acid as starting material and is available commercially as a tromethamine salt (Monurol) for oral consumption and as a disodium salt for intravenous use. It is currently registered in 14 European countries, Japan, and various other countries and is undergoing clinical development in the US.

Fosfomycin has a unique chemical structure that is distinct from all other marketed classes of antimicrobial agents (i.e.,  $\beta$ -lactams, glycopeptides, fluoroquinolones, macrolides, lincosamides, tetracyclines, and aminoglycosides). Fosfomycin has a low molecular mass, is freely soluble in water, has negligible plasma protein binding *in vivo*, and distributes

predominantly into the extracellular space fluid of the body (approximately 0.30 L/kg body weight or a steady state volume of distribution is 18–27 L) [13–18]. Fosfomycin is able to penetrate into human lymphocytes where it elicits an effect against pathogens that have survived initial phagocytosis by neutrophils and increases intracellular killing of pathogens [19, 20].

Fosfomycin tromethamine has an oral bioavailability of 30–37% and a mean serum half-life of 5.7 h [13, 14]. After intravenous administration of a 4 to 8 g dose of fosfomycin, mean peak serum concentrations are commonly in the range of 200 to 400  $\mu$ g/mL [16, 21]. Fosfomycin is excreted predominantly in the urine in a nonmetabolized form [21]. Fosfomycin demonstrates greater antibacterial activity in weakly acidic environments (pH, 6.0). This property combined with its propensity for excretion as an active molecule in urine underlies its most common use as prophylaxis and treatment of urinary tract infections.

Fosfomycin exerts its antibacterial activity by inactivating UDP-*N*-acetylglucosamine-3-enolpyruvyl transferase (MurA), the enzyme responsible for ligating phosphoenolpyruvate (PEP) to the 3'-hydroxyl group of UDP-*N*-acetylglucosamine in the first step of peptidoglycan synthesis (conversion of UDP-*N*-acetylglucosamine to UDP-*N*-acetylmuramic acid) [13, 15, 16, 18, 22]. Fosfomycin is a PEP analog that inhibits MurA by alkylating an active site cysteine residue (Cys 115 in the *Escherichia coli* MurA enzyme). MurA is essential for any bacterium possessing muramic acid in its cell wall and accounts for fosfomycin's broad-spectrum activity and its bactericidal mechanism of action. In addition, fosfomycin has been demonstrated to reduce adherence of bacteria to uroepithelial cells. Fosfomycin accesses the bacterial cytosol primarily via the inducible hexose phosphate transport (UhpT) pathway but also gains entry using the constitutively expressed glycerol-3-phosphate transport (GlpT) pathway.

Limited data indicate that fosfomycin acts in a time-dependent manner with time above MIC ( $T > MIC$ ) as the pharmacodynamic (PD) parameter associated with bacteriological efficacy [23]. Recent *in vivo* data (a neutropenic murine thigh infection model), however, published by Lepak et al. indicated that the  $AUC > MIC$  ratio was the pharmacodynamic parameter most closely linked to efficacy ( $R^2$ , 0.70) in Gram-negative bacteria (*E. coli*, *K. pneumoniae*, and *P. aeruginosa*) [24].  $AUC/MIC$  ratios associated with static effects against *E. coli*, *K. pneumoniae*, and *P. aeruginosa* were 24, 21, and 15, respectively [24]. Based on target attainment of 70–100%, comparable efficacy for all isolates tested by Lepak et al. was achieved using  $T > MIC$  [24]. At this time, it is not yet clear which fosfomycin PK/PD parameter is best associated with microbiological eradication, prevention of resistance, and clinical efficacy. As well, at this time, it is not yet known which pharmacodynamic targets should be achieved with fosfomycin and which doses should be used to achieve these PK/PD targets. There is also considerable evidence from animal models that fosfomycin can penetrate into biofilms and, in combination with other antimicrobial agents, possesses efficacy in eradicating a variety of biofilm-associated pathogens [25–28]. Recent data on fosfomycin's biofilm activity were reviewed by Falagas et al. [29].

#### 4. Fosfomycin: Antimicrobial Susceptibility Testing

Standardized methods for antimicrobial susceptibility testing of fosfomycin are published by the Clinical and Laboratory Standards Institute (CLSI) [30] and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [31]. Most Canadian clinical microbiology laboratories follow CLSI guidelines. It is important to recognize that there are differences in the organisms for which fosfomycin MIC and zone diameter breakpoints apply in CLSI and EUCAST guidelines. As well, there are numerical differences in fosfomycin MIC and zone diameter breakpoints between CLSI and EUCAST methods, and these differences need to be considered when reading and comparing publications generated using different antimicrobial susceptibility testing methods.

Currently, CLSI-approved susceptibility breakpoints for fosfomycin exist only for *E. coli* and *E. faecalis*, with an MIC  $\leq 64 \mu\text{g/mL}$  (disk diffusion zone diameter:  $\geq 16 \text{ mm}$ ) considered susceptible (resistance: MIC  $\geq 256 \mu\text{g/mL}$ ; disk diffusion zone diameter:  $\leq 12 \text{ mm}$ ); CLSI has only approved fosfomycin for testing isolates from urinary tract infections (acute uncomplicated cystitis following a single oral dose) [30]. EUCAST breakpoints for fosfomycin only exist for Enterobacteriaceae and staphylococci [31]. For Enterobacteriaceae, an MIC of  $\leq 32 \mu\text{g/mL}$  (for *E. coli* only: disk diffusion zone diameter  $\geq 24 \text{ mm}$ ) is considered susceptible for both intravenous (systemic infections but may be dose dependent) and oral (uncomplicated urinary tract infection only) fosfomycin (resistance: MIC,  $> 32 \mu\text{g/mL}$ ; for *E. coli* only: disk diffusion zone diameter,  $< 24 \text{ mm}$ ) [31]. It is of note that agar dilution, not broth dilution, is the only approved MIC method for fosfomycin testing [30, 31] and that single colonies growing within the inhibitory zone of a disk diffusion test should be ignored as they do not indicate resistance [31]. Further EUCAST recommendations for disk diffusion zone diameter for *K. pneumoniae* are planned to be published in 2018. Further work is ongoing regarding *P. aeruginosa* and *S. aureus* (EUCAST, personal communication). For staphylococci, an MIC of  $\leq 32 \mu\text{g/mL}$  (disk diffusion zone size not available) is considered susceptible for intravenous (systemic infections) fosfomycin only (resistance,  $> 32 \mu\text{g/mL}$ ); oral susceptibility breakpoints are not published by EUCAST for testing staphylococci against fosfomycin [31]. EUCAST breakpoints suggest that when considering the potential use of intravenous fosfomycin (i.e., the potential spectrum of activity of fosfomycin), isolates (genus/species) with MICs  $\leq 32 \mu\text{g/mL}$  may be considered susceptible and those with MICs  $> 32$  should likely be considered resistant. EUCAST also states that wild-type isolates of *P. aeruginosa* with MICs of  $\leq 128 \mu\text{g/mL}$  (epidemiological cutoff value) have been successfully treated with combinations of fosfomycin (oral and intravenous) and other agents. Therefore, in reviewing studies, the focus should be on MICs for fosfomycin and not necessarily on the reported percentages of isolates that are susceptible, and it is important to realize that depending on the IV dosage used of fosfomycin, greater target attainment can be achieved with greater fosfomycin daily doses. Also, studies reporting in vitro susceptibility

testing of fosfomycin prior to 1983 should be disregarded as the importance of adding physiological concentrations of glucose-6-phosphate to testing media (to allow fosfomycin to exhibit its full antimicrobial activity) was unknown before that time [13]. Antimicrobial susceptibility testing (agar dilution or disk diffusion) requires agar supplementation with  $25 \mu\text{g/mL}$  of glucose-6-phosphate to ensure induction of the hexose phosphate transport (UhpT) pathway. Further, studies based upon broth dilution MIC testing should not be considered because of the relatively high likelihood of spontaneous mutation to fosfomycin resistance in broth [13].

Given the factors described in the preceding paragraphs, it is paramount to ensure that readers of susceptibility and clinical studies describing the activity of fosfomycin understand the parameters under which in vitro activity was defined. In this review, only MICs (and not susceptibility rates) are presented in the in vitro susceptibility testing data tables (Tables 2 and 3) describing the activity of fosfomycin against Gram-positive and Gram-negative bacteria.

#### 5. Fosfomycin: Activity against Gram-Positive Bacteria

In general, fosfomycin possesses broad-spectrum activity against both Gram-positive and Gram-negative bacterial pathogens. The in vitro activity of fosfomycin against Gram-positive bacteria is summarized in Table 2 [13, 29, 31–34]. Fosfomycin is active against *S. aureus* (MIC<sub>50</sub>  $4 \mu\text{g/mL}$ ), including both MSSA and MRSA strains (Table 2). Fosfomycin is also active against *S. epidermidis* (MIC<sub>50</sub>  $4 \mu\text{g/mL}$ ) but displays limited activity against *S. saprophyticus* (MIC<sub>50</sub>  $64\text{--}128 \mu\text{g/mL}$ ). In the case of *Enterococcus* spp., fosfomycin displays activity against both *E. faecalis* and *E. faecium* (MIC<sub>50</sub>  $32\text{--}64 \mu\text{g/mL}$ ), including VRE (Table 2). In the case of *Streptococcus* spp., fosfomycin displays activity against *S. pneumoniae*, *S. pyogenes*, and *S. agalactiae* with MIC<sub>50</sub>  $8\text{--}32 \mu\text{g/mL}$  [31]. Some streptococci, corynebacteria, *Chlamydia*, and mycoplasmas are resistant to fosfomycin, likely due to the absence or low abundance of the MurA target.

#### 6. Fosfomycin Properties: Activity against Gram-Negative Bacteria

The in vitro activity of fosfomycin against Gram-negative bacteria is summarized in Table 3 [13, 29, 31–35]; it includes activity against ESBL-producing and AmpC-producing Enterobacteriaceae (MIC<sub>50</sub>  $0.5\text{--}32 \mu\text{g/mL}$ ). The antibacterial spectrum of fosfomycin includes *Haemophilus* spp. (MIC<sub>50</sub>  $1 \mu\text{g/mL}$ ) and the majority of enteric Gram-negative bacteria but demonstrates higher MICs for *Morganella morganii* (MIC<sub>50</sub>  $128\text{--}256 \mu\text{g/mL}$ ). Activity against *Klebsiella* and *Enterobacter* is variable (MIC<sub>50</sub>  $4\text{--}32 \mu\text{g/mL}$ ) (Table 3). Fosfomycin is moderately active against *P. aeruginosa* with variable MICs ranging from 4 to  $> 512 \mu\text{g/mL}$  (MIC<sub>50</sub>  $32\text{--}64 \mu\text{g/mL}$ ). *Acinetobacter* spp. (MIC<sub>50</sub>  $128 \mu\text{g/mL}$ ) and *Stenotrophomonas maltophilia* (MIC<sub>50</sub>  $64\text{--}128 \mu\text{g/mL}$ ) are poorly susceptible to fosfomycin. Gram-negative anaerobic bacteria are also not part of fosfomycin's antibacterial spectrum.

TABLE 2: In vitro activity of fosfomycin against aerobic and facultative Gram-positive bacteria (cumulative data from [13, 29, 31–34]).

Organism	Number of isolates tested	Fosfomycin		
		MIC <sub>50</sub> (µg/mL)	MIC <sub>90</sub> (µg/mL)	Range (µg/mL)
<i>Enterococcus faecalis</i>	1965	32–64	64	0.5–512
<i>Enterococcus faecium</i>	620	32–64	64–128	0.5–128
<i>Enterococcus</i> spp.	137	16–32	64	0.25–>256
<i>Staphylococcus aureus</i>	2213	4	16	0.12–512
<i>Staphylococcus aureus</i> , MSSA	103	4	4	0.5–16
<i>Staphylococcus aureus</i> , MRSA	263	4	8–64	0.5–512
<i>Staphylococcus epidermidis</i>	896	8	128	0.5–256
<i>Staphylococcus saprophyticus</i>	309	64–128	256–>512	2–>512
<i>Streptococcus pneumoniae</i>	57	8	16	4–32
<i>Streptococcus pyogenes</i>	150	32	64	2–64
<i>Streptococcus agalactiae</i>	154	8–32	64	1–64

TABLE 3: In vitro activity of fosfomycin against aerobic and facultative Gram-negative bacteria (cumulative data from [13, 29, 31–35]).

Organism	Number of isolates tested	Fosfomycin		
		MIC <sub>50</sub> (µg/mL)	MIC <sub>90</sub> (µg/mL)	Range (µg/mL)
<i>Acinetobacter</i> spp.	244	128	128–512	0.25–512
<i>Citrobacter</i> spp. ( <i>C. diversus</i> , <i>C. freundii</i> , and <i>C. koseri</i> )	437	0.5–2	1–4	≤0.12–64
<i>Enterobacter</i> spp. ( <i>E. agglomerans</i> , <i>E. aerogenes</i> , and <i>E. cloacae</i> )	808	8–32	16–256	0.25–>512
<i>Escherichia coli</i>	7735	0.5–4	1–16	0.25–512
<i>Escherichia coli</i> ESBL-producing	296	2	4	≤1–512
<i>Escherichia coli</i> AmpC-producing	135	2	4–16	≤1–>512
<i>Haemophilus influenzae</i>	50	1	4	1–128
<i>Klebsiella oxytoca</i>	153	8	16–32	1–64
<i>Klebsiella pneumoniae</i>	284	4–16	16–128	≤2–512
<i>Klebsiella</i> spp.	788	16	32–128	≤2–512
<i>Morganella morganii</i>	59	128–256	512	8–>512
<i>Proteus mirabilis</i>	1533	1–4	8–64	≤0.12–>512
<i>Proteus vulgaris</i> (indole-positive <i>Proteus</i> )	431	≤2–16	8–256	0.5–256
<i>Providencia</i> spp. ( <i>P. rettgeri</i> and <i>P. stuartii</i> )	164	2–16	8–128	≤2–512
<i>Pseudomonas aeruginosa</i>	1450	32–64	64–128	2–>512
<i>Pseudomonas</i> spp.	35	128	256	≤0.5–512
<i>Serratia marcescens</i>	383	8	16–32	0.5–128
<i>Shigella</i> spp.	185	2	2	0.5–64
<i>Stenotrophomonas maltophilia</i>	151	64–128	128	16–512

Activity against ESBL-producing pathogens, notably ESBL-producing *E. coli*, MDR *E. coli* [35], as well as ESBL and KPC-producing *K. pneumoniae* [36], is good to excellent (MIC<sub>50</sub> 0.5–16 µg/mL), because fosfomycin is not affected by cross resistance associated with mechanisms of resistance to other agents. Kaase et al. tested 80 isolates of Enterobacteriaceae with various carbapenemases (KPC, VIM, NDM, and OXA-48) and reported that 78% had MICs ≤32 µg/mL and would thus be considered susceptible according to the EUCAST breakpoint [31, 37].

## 7. Fosfomycin: Resistance Mechanisms and Prevalence of Resistance

Resistance to fosfomycin most commonly arises via mutations in the chromosomal genes encoding the GlpT (primary mechanism of resistance) and UhpT (less common mechanism of resistance) pathways, thereby impeding fosfomycin's entry into bacterial cells and reducing access to its

target site via the cytosol [22, 38–40]. Resistance to fosfomycin may also result less commonly from a myriad of other mechanisms including modification, inactivation, or overexpression of its target site enzyme (MurA), fosfomycin kinases (e.g., *fomA* and *fomB*), or inactivation via plasmid- and chromosomally encoded enzymes (e.g., *fosA*, *fosB*, and *fosX*) [16, 41, 42].

*Fos* enzymes are members of the glyoxalase superfamily and inactivate fosfomycin by catalyzing its conjugation with glutathione. These enzymes function by nucleophilic attack on carbon 1 of fosfomycin, which opens the epoxide ring and renders it ineffective. The enzymes differ by the identity of the nucleophile utilized in the reaction: glutathione for FosA, bacillithiol for FosB [43, 44], and water for FosX [40]. In general, FosA and FosX enzymes are produced by Gram-negative bacteria, whereas FosB is produced by Gram-positive bacteria [40]. Another enzyme, FosC, utilizes ATP and adds a phosphate group to fosfomycin, thus altering its properties and making the drug ineffective [45].

TABLE 4: Comparative clinical studies describing outcomes for patients receiving intravenous fosfomycin in combination with a second antimicrobial agent.

Trial design (reference) Infection type (n)	Treatment regimens and outcomes	Pathogens
Open label nonrandomized [55] Septicemia (32), osteoarthritis (1), meningitis (1), and pulmonary infection (1)	Group 1: 17 patients fosfomycin (237.1 mg/kg daily IV)/penicillin Cure: 16/17 (94.1%)	MSSA
	Group 2: 18 patients gentamicin/penicillin Cure: 14/18 (77.7%)	
Prospective randomized [56] Ventilator-associated pneumonia (22) and pneumonia (10)	Group 1: 17 patients fosfomycin (12 g daily IV)/ampicillin Cure: 10/17 (58.8%); improvement: 6/17 (35.2%)	<i>E. coli</i> , coagulase-positive staphylococci, <i>P. aeruginosa</i> , and <i>Klebsiella</i>
	Group 2: 15 patients gentamicin/ampicillin Cure: 7/15 (46.6%); improvement: 5/15 (33.3%)	

Resistance development during therapy is a confounding issue for fosfomycin [46, 47]. In vitro studies have shown that fosfomycin is associated with the development of resistance at a rate of one cell in every  $10^6$  to  $10^8$  cells [16, 18], thereby generating concerns regarding the emergence of resistance during therapy. However, these concerns have not been realized as the frequency of mutational resistance in vitro has not been observed in clinical studies or in settings of prolonged use, suggesting that there is a biological cost associated with such mutations (e.g., a decreased growth rate or, in the case of urinary tract infections, a reduced capacity for adherence) [16]. Data from the Antimicrobial Resistance Epidemiological Survey on Cystitis study showed that resistance to fosfomycin remained rare (~2%) in regions where it was widely used [48]. Surveys of developing resistance patterns in Europe have also not revealed any major increases in plasmid-mediated resistance to fosfomycin [16]. Other possible explanations for fosfomycin's low resistance rate in urinary tract infections include its short contact time, high urine concentration (706 ( $\pm$ 466)  $\mu$ g/mL, 2–4 h after a single oral 3 g dose), and potentially higher compliance compared with agents dosed for 3–5 days. Lower frequencies of resistance development have been observed at higher fosfomycin concentrations and in media with an acidic pH [16]. In vitro resistance development in *E. coli* is less frequent than that in *K. pneumoniae* and *P. aeruginosa*, whereas relevant data for other Enterobacteriaceae are relatively scarce [15, 16].

Karageoropoulos et al. reported that resistance emerged in 2.3–6.7% of cases where fosfomycin was used for a clinical indication other than complicated urinary infections (e.g., in respiratory tract infections or osteomyelitis) apart from one study of suppurative otitis where the rate was 13.3% [16]. Considering clinical studies published before 2012, pathogens that most frequently arose as resistant to fosfomycin were *P. aeruginosa*, *Proteus* spp., *Klebsiella* spp., and *Enterobacter* spp. [16]. A more recent review undertook a similar investigation and reviewed 15 clinical studies that reported the use of intravenous fosfomycin in monotherapy and reported on resistance development during treatment [49]. In four of the 15 studies, no resistant isolate was identified after fosfomycin treatment. The remaining studies reported levels of resistance ranging from <3% to 17.9% [49]. In that review, the pooled

estimate for resistance development during fosfomycin therapy was 3.4% (95% CI: 1.8–5.1%) [49]. Nonetheless, given that resistance to fosfomycin has the potential to develop in vivo when it is used as monotherapy, convention dictates that fosfomycin be administered as a component of combination therapy with one or more other antimicrobial agents when used for systemic therapy, except for the treatment of complicated urinary tract infections where it may be used as monotherapy [15, 50, 51].

## 8. Intravenous Fosfomycin: Clinical Trials and Clinical Utility

Few sufficiently powered, randomized, double-blind, placebo-controlled clinical trials comparing intravenous fosfomycin, alone or in combination, to a standard therapy can be found in the published literature. Instead, the published literature describing the use of intravenous fosfomycin, alone or in combination, is comprised of >1,000 case reports, case series, and cohort descriptive studies (summarized in [13, 15, 16, 29, 49, 52–54]); many of these studies are published in German, Spanish, French, Japanese, and Chinese. The limited number of robust clinical trials, in the English language scientific literature, aimed at determining the therapeutic and prophylactic value of using fosfomycin in combination with a second antimicrobial agent are listed in Tables 4 and 5 [55–58]. Additional, non-English language clinical trials have been summarized by Grabein et al. [49].

Grabein et al. recently performed a systemic review and meta-analysis of the clinical literature describing the use of intravenous fosfomycin from its inception to July 2016 [49]. Their meta-analysis summarized the utility of intravenous fosfomycin in >100 published studies involving >5,000 patients [49]. The majority of studies (~90%, 113/128 studies) available for review were conducted in European countries or Japan and 84 of the 128 studies were published before 1989 [49]. Approximately 50% of the studies were retrospective case series, with only a minority of studies (6%; 8/128 studies) being randomized controlled trials [49]. The randomized controlled trials comparing intravenous fosfomycin therapy (either monotherapy or combination therapy) against another therapy regimen were generally of

TABLE 5: Comparative clinical studies describing outcomes for patients receiving prophylaxis with intravenous fosfomycin in combination with a second antimicrobial agent.

Trial design (reference) Operation type	Treatment regimens and outcomes
Multicenter, double-blind, randomized [57] Elective colorectal surgery	Group 1: 259 patients received fosfomycin (8 g IV)-metronidazole before operation and second infusion of fosfomycin (8 g IV) 8 h later Abdominal infection in 12/259 (4.6%) of patients; pneumonia in 13/259 patients (5.0%) Group 2: 258 patients received doxycycline-metronidazole before operation and second identical infusion 8 h later Abdominal infection in 19/258 (7.4%) of patients; pneumonia in 5/258 patients (2.0%)
Prospective double-blind randomized [58] Elective colorectal surgery	Group 1: 72 patients, 3 days before operation received placebo, 1 h before operation received fosfomycin-metronidazole (8 g IV) Infective complications in 9/72 (12.5%) of patients Group 2: 77 patients, 2 days before operation received bacitracin-neomycin, 1 day before operation received metronidazole, 1 h before operation received ampicillin Infective complications in 8/77 (10.4%) of patients

only poor or fair quality due to a lack of statistical power or the presence of possible confounding variables [49]. No difference in clinical (odds ratio 1.44) or microbiological efficacy (odds ratio 1.28) between intravenous fosfomycin and other antimicrobial agents was observed in comparative trials [49]. Grabein et al. also reported that, in general, intravenous fosfomycin demonstrated a favorable safety profile, with only mild adverse effects (e.g., mild hypokalemia due to high sodium load with administration of fosfomycin disodium) not requiring discontinuation of therapy [49]. Other reviews and studies have reported similar conclusions [13, 15, 16, 51, 52, 59].

More recently, in 2017, Zavante Therapeutics completed a Phase III clinical trial through the U.S. FDA (ClinicalTrials.gov identifier: NCT02753946) that studied the safety and efficacy of intravenous fosfomycin 6 g every 8 h (ZTI-01) versus piperacillin-tazobactam 4.5 g every 8 h (each administered for 7 days) for the treatment of complicated urinary tract infections or acute pyelonephritis in hospitalized patients (details of this study discussed later). Two other Phase III clinical trials are currently registered in ClinicalTrials.gov (U.S. National Library of Medicine) that involve intravenous fosfomycin and are currently recruiting participants. The first is a study of fosfomycin versus meropenem for the treatment of bacteremic patients with urinary tract infection due to multidrug-resistant *E. coli* (ClinicalTrials.gov identifier: NCT02142751), and the second is a study to determine whether the combination of daptomycin and fosfomycin is superior to daptomycin alone in the treatment of MRSA bacteremia (ClinicalTrials.gov identifier: NCT01898338).

Intravenous fosfomycin will likely be used in combination with an antimicrobial agent belonging to another class (e.g.,  $\beta$ -lactams, aminoglycosides, fluoroquinolones, glycopeptides, or glycolipopeptides) when used to treat serious or systemic infections outside of the urinary tract.

The combination partner of intravenous fosfomycin would be selected according to indication and patient's individual clinical situation. Fosfomycin can be combined with all other antimicrobial classes according to type of infection and causative pathogens. The rationale for combining fosfomycin with a second agent is primarily based on preventing the emergence of fosfomycin resistance [60] and broadening the antimicrobial spectrum. Combination therapy may also offer additive or synergistic activity/efficacy and attractive pharmacokinetic properties for difficult to reach compartments [61]. The true benefit of adding fosfomycin to another antimicrobial agent for patient therapy is poorly described as published clinical studies are rarely structured to compare fosfomycin and the other agent alone and then in combination. Of interest, combination therapy data with fosfomycin in biofilm animal models have shown better results compared to fosfomycin monotherapy [25, 26]. Experts suggest that the use of the highest dose of fosfomycin should be considered in the treatment of systemic infections to combat the potential for resistance development [16].

As mentioned earlier, fosfomycin allocates extensively into extracellular space fluid [13] and distributes rapidly into tissues [15, 62], achieving clinically relevant concentrations in sites such as serum, soft tissues, lung, bone, CSF, abscess fluid, and endocardial tissue. Fosfomycin's rapid penetration into tissues is a highly desirable characteristic for the treatment of serious infections. The highest peak concentrations of fosfomycin are achieved in serum and urine following intravenous administration [15, 52], whereas the concentrations of fosfomycin achieved in lung (50–60% of serum concentration), bone (50%), CSF (20–50%), soft tissues (75%), and other tissues are lower than those in serum [62–64].

The case reports, case series, cohort descriptive studies, and clinical trials describing the use of fosfomycin in combination with other antimicrobial agents can be grouped into

studies of CNS infections, respiratory infections, complicated urinary tract infections, infectious endocarditis and septicemia, osteomyelitis, and soft tissue infections. Overall, cure rates of >80% have been observed [15, 29, 49, 52].

**8.1. CNS Infections.** Fosfomycin can pass through the blood-brain barrier in both healthy and inflamed meninges [23]. Inflammation increases the penetration rate of fosfomycin across the meninges [23]. Fosfomycin crosses the blood-brain barrier independent of inflammation and reaches therapeutic concentrations within the CSF within 2 h of receiving an 8-g intravenous dose [23]. In the area of CNS infections (meningitis), a number of studies have shown the efficacy of fosfomycin combined with an aminoglycoside or cefotaxime in the treatment of meningitis due to Gram-negative bacilli (*H. influenzae* and *E. coli*), *Neisseria meningitidis*, *S. aureus*, and, recently, pneumococci with reduced susceptibility to penicillin (MIC, >0.1 µg/mL) [17]. In patients who received a 5-g dose, three times daily, fosfomycin concentrations of >30 µg/mL were reached in the CSF by the second day of treatment [17]. Fosfomycin may have utility in the treatment of ventricular shunt infections where the pathogens are frequently resident flora of skin and mucus membranes (e.g., coagulase-negative staphylococci). These infections are known to cause only minor inflammatory changes at the blood-brain barrier, making fosfomycin an attractive therapy, given its ability to cross intact meninges and achieve therapeutic concentrations.

**8.2. Respiratory Tract Infections.** In the treatment of respiratory tract infections (nosocomial pneumonia), particularly when *P. aeruginosa* and *S. aureus* are pathogens, combinations of fosfomycin with a ureidopenicillin or ceftazidime (for *P. aeruginosa*) or vancomycin (for *S. aureus*) have proven effective. A 1986 randomized controlled trial compared the effectiveness of intravenous fosfomycin (4 g every 8 h) versus gentamicin (80 mg every 8 h), both combined with ampicillin in critically ill patients with pneumonia [56]. Relatively high clinical success rates were observed in both treatment groups (94% ( $n = 17$ ) versus 80% ( $n = 15$ )). When dosing fosfomycin at 2 g, serum concentrations attained were 32 µg/mL, 1–2 h post-intravenous administration; lung concentrations were 32–52% of corresponding serum concentrations [65]. When dosed at 4 g, fosfomycin serum concentrations were 243 µg/mL, 1 h following intravenous administration; lung concentrations were 54% and 44% of corresponding serum concentrations in healthy and infected lung tissue, respectively [66].

The place of fosfomycin in the treatment of *P. aeruginosa* infections is still poorly established [29, 53, 67]. However, favorable results for combinations of fosfomycin with an aminoglycoside have been reported in cases of cystic fibrosis in children with episodes of superinfection involving *P. aeruginosa*.

**8.3. Complicated Urinary Tract Infections.** Severe urinary tract infections have been treated with fosfomycin monotherapy in view of the excellent urinary elimination of this

agent [16]. Favorable results have been obtained in severe pyelonephritis (various doses/routes used), with sterilization of the urine obtained in 79% of cases at the end of treatment (7 days) [16]. The lack of nephrotoxicity of fosfomycin in patients suffering from parenchymal renal infection, together with the antibacterial spectrum of fosfomycin (i.e., includes enteric Gram-negative bacilli), suggests reliable efficacy in the treatment of these infections [68]. Several reviews of studies have suggested that fosfomycin is in association with favorable outcomes (versus comparators) when treating with MDR Gram-negative bacterial infections, predominantly urinary tract infections [16, 51–53, 60].

More recently, in 2017, the ZEUS study, a multicentered, randomized, double-blind phase II/III study of hospitalized patients with complicated urinary tract infections or pyelonephritis received a 1-h infusion of 6 g fosfomycin every 8 h (18 g total daily dose) or a 1-h infusion of 4.5 g piperacillin-tazobactam every 8 h (13.5 g total daily dose) for 7 days [51]. Patients with concurrent bacteremia received 14 days of treatment. Oral step-down therapy was prohibited. Overall success rates for patients with complicated urinary tract infections or acute pyelonephritis were numerically higher for fosfomycin (64% or 119/164) than for piperacillin-tazobactam (54.5% or 97/178). Overall success rates for patients with complicated urinary tract infections were numerically higher for fosfomycin (64%) than for piperacillin-tazobactam (42%), whereas for acute pyelonephritis, success rates were similar between treatment groups, 68% (fosfomycin) versus 66% (piperacillin-tazobactam) [51]. Microbiological eradication rates were numerically higher in the fosfomycin group than in the piperacillin-tazobactam group (66% versus 56%), whereas clinical cure rates were similar between treatment groups, 91% (fosfomycin) versus 92% (piperacillin-tazobactam) [51]. IV fosfomycin was well tolerated with most frequent treatment-related adverse effects being gastrointestinal in nature along with hypokalemia (primarily mild) due to the high sodium load of administering fosfomycin disodium.

**8.4. Infectious Endocarditis.** Fosfomycin is recommended for the treatment of staphylococcal endocarditis as an alternative therapy by the current European Society of Cardiology guideline for the management of infective endocarditis [69]. Del Rio et al. evaluated the efficacy of fosfomycin in combination with imipenem in a multicentered trial including 12 patients with infective endocarditis, who had previously received unsuccessful treatment with other antimicrobial regimens [70]. The authors reported a clinical success rate of 69% and only one death related to MRSA infection [70]. Furthermore, negative blood cultures were achieved in all cases 72 h after treatment [70]. The combination of fosfomycin and an aminoglycoside has been found to be consistently rapidly bactericidal (95%) [71] and effective in treating staphylococcal septicemia [72, 73]. In endocarditis, the results of use of fosfomycin vary: poor in the case of viridans group streptococci (which may not be part of the antibacterial spectrum of fosfomycin) but more favorable in staphylococcal endocarditis, where the combination of fosfomycin with an aminoglycoside for *S. aureus* or with a fluoroquinolone for

MRSA has demonstrated efficacy [73]. In *Staphylococcus epidermidis* infections, the limited number of active antibacterial agents may promote fosfomycin to a position of choice, given it is combined with vancomycin, an aminoglycoside, or a fluoroquinolone. In *P. aeruginosa* septicemia, cure rates on the order of 83% have been reported [74].

**8.5. Osteomyelitis.** There is considerable clinical experience using fosfomycin in combination regimens for various types of bone infections, primarily complicated fractures and osteomyelitis or septic arthritis in children [17]. Fosfomycin penetrates well into osseous tissue. After a 5 g or 10 g intravenous dose, fosfomycin concentrations in bone and interstitial space fluids were 117–119  $\mu\text{g}/\text{mL}$  and 368–451  $\mu\text{g}/\text{mL}$ , respectively [62, 75]. Because of its good diffusion into bone, fosfomycin has the potential to be recommended in the treatment of staphylococcal bone and joint infections (osteomyelitis). For this indication, fosfomycin is recommended to be combined with oxacillin (for MSSA) in chronic osteomyelitis or with an aminoglycoside or fluoroquinolone in septicemia with an osteoarticular localization [62, 75].

**8.6. Skin and Soft Tissue Infections.** There are also clinical data to support the use of fosfomycin in the treatment of soft tissue infections. In diabetic foot infections, median fosfomycin tissue concentrations of  $\geq 22$ –25  $\mu\text{g}/\text{mL}$  were measured (200 mg/kg of body weight corresponding to 3 doses  $\times$  5 g fosfomycin/day); measured concentrations were comparable for inflamed and noninflamed tissues [63]. A multicenter study has evaluated treatment with fosfomycin (8–24 g daily) in combination with a conventional agent for patients with limb-threatening diabetic foot infections. Limb preservation was achieved in the great majority (48/52) of patients [76]. Legat et al. also reported that a daily dose of 15 g of fosfomycin (3 doses  $\times$  5 g) maintained sufficient fosfomycin concentrations in the interstitial space fluid of inflamed tissues to inhibit the growth of relevant bacteria, such as *S. aureus*, when treating cellulitis and diabetic foot infections [63].

## 9. Summary of Fosfomycin Properties

Fosfomycin inhibits cell wall synthesis, resulting in bactericidal activity using a mechanism different from that of  $\beta$ -lactams. It is a broad-spectrum agent with activity against a variety of Gram-positive and Gram-negative bacteria. Fosfomycin's unique mechanism of action allows it to be active against organisms resistant to a variety of other antimicrobial classes, including MRSA, VRE, MDR *E. coli*, MDR *Klebsiella* spp., and some MDR *P. aeruginosa*. Studies assessing potential for resistance demonstrate that fosfomycin resistance is associated with a biological cost to the pathogen making resistant subpopulations less fit for *E. coli* but not for *P. aeruginosa* [77]. Fosfomycin when used in combination with a variety of antimicrobials (e.g.,  $\beta$ -lactams, carbapenems, and aminoglycosides) has demonstrated in vitro additivity and even synergistic activity. Fosfomycin due, in part, to its low molecular weight achieves extensive tissue distribution

including difficult to reach compartments such as aqueous humor, vitreous humor, abscess fluid, and CSF.

Clinically, intravenous fosfomycin has been used to treat a variety of infections including: urinary tract infections, gastrointestinal infections, meningitis, pulmonary infections including cystic fibrosis, endocarditis, ocular infections, postoperative wound infections, osteomyelitis, obstetric and gynecological infections, intra-abdominal infections, diabetic foot infections, shunt infections, and bloodstream infections [13, 15, 16, 29, 49, 52–54]. The most common bacteriologic infectious causes treated by fosfomycin have been MDR *S. aureus*, MDR *S. epidermidis*, antimicrobial-resistant Enterobacteriaceae, and MDR *P. aeruginosa*. Frequently, fosfomycin was administered to patients after initially failing first- and sometimes second-line antimicrobials and was frequently used in combination with other antimicrobial agents such as  $\beta$ -lactams, fluoroquinolones, aminoglycosides, vancomycin, and rifampin. Clinical resolution of infections with fosfomycin treatment occurred in ~80% of treated patients.

Intravenous fosfomycin has been available and used extensively in a variety of countries for over 40 years and has demonstrated exceptional safety including in neonates and children, even with long-term administration (weeks). Adverse effects, which are not common and mild in nature, are primarily gastrointestinal in nature and as well hypokalemia. Available data suggest that to date, no clinically relevant pharmacological interactions between fosfomycin and other agents, including drugs, stimulants, or food, have been reported.

## 10. Role of Intravenous Fosfomycin in Canada

The availability of intravenously administered fosfomycin in Canada revolves primarily around its potential use in treating hospitalized patients with MDR Gram-positive and MDR Gram-negative infections not responding to other antimicrobial agents and/or for patients who cannot tolerate first- and/or second-line agents due to adverse effects. With MRSA rates in Canada at ~20%, VRE rates at 6% and rising, rates of ESBL-positive *E. coli* and *Klebsiella* spp. at ~12% and ~7%, respectively, and rising, and MDR *P. aeruginosa* at 6.5%, fosfomycin is needed for use in combination with standard antimicrobials in place of toxic drugs such as aminoglycosides, tigecycline, and colistin.

Intravenous fosfomycin was recently added by the World Health Organization (WHO) to its list of essential medicines for treatment of adults and children. It is listed among the WHO's RESERVE group of antibacterial medicines as a treatment option for highly specific patients and settings when other alternatives would be inadequate (e.g., biofilm-related infections, deep-seated focus, abscess formation, severe allergy, resistance to standard therapy, severe clinical condition, presence of comorbidities, or intolerance of standard therapy) or have already failed (e.g., serious life-threatening infections due to MDR bacteria). Other members of the RESERVE group are aztreonam, cefepime, ceftaroline, polymyxin B, colistin, linezolid, tigecycline, and daptomycin.

Intravenous fosfomycin's role in Canadian hospitals would be as therapy for patients with infections who have

not responded to first- and potentially second-line antimicrobials or in patients who cannot tolerate (due to adverse effects) first- and second-line antimicrobials. Intravenous fosfomycin would primarily be used in combination with  $\beta$ -lactams, carbapenems, fluoroquinolones, aminoglycosides, and glycopeptides/glycolipopeptides for the treatment of MDR MRSA, MDR methicillin-resistant *S. epidermidis* (MRSE), MDR VRE, MDR Enterobacteriaceae, and MDR *P. aeruginosa* infections. Using fosfomycin in combination with another antimicrobial should limit the development of resistance to this agent over time. Because of its proven safety, it should be considered for use in preference to last line toxic agents such as colistin, tigecycline, and aminoglycosides. In addition, due to its exceptional tissue distribution it could be used not only for the most common infections such as bacteremia, urinary tract, skin and soft tissue, and respiratory infections but also for difficult to treat infections such as bone infections, meningitis, and invasive ocular infections. Finally, based upon the results of the ZEUS study, IV fosfomycin would be a preferred option for treating cUTI due to resistant Enterobacteriaceae.

## Conflicts of Interest

Dr. George Zhanel is a consultant for Verity Pharma (Toronto, Canada).

## References

- [1] <http://www.who.int/drugresistance/documents/surveillancereport/en/2017>.
- [2] J. S. Bradley, R. Guidos, S. Baragona et al., "Anti-infectives research and development problems challenges and solutions," *The Lancet Infectious Diseases*, vol. 7, no. 1, pp. 68–78, 2007.
- [3] H. Grundmann, D. M. Livermore, C. G. Giske et al., "Carbapenem-non-susceptible *Enterobacteriaceae* in Europe: conclusions from a meeting of national experts," *Euro-surveillance*, vol. 15, no. 46, article 19711, 2010.
- [4] G. G. Zhanel, M. DeCorby, N. Laing et al., "Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005–2006," *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 4, pp. 1430–1437, 2008.
- [5] G. G. Zhanel, M. DeCorby, H. Adam et al., "Prevalence of antimicrobial resistant pathogens in Canadian hospitals: results of the Canadian ward surveillance study (CANWARD 2008)," *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 11, pp. 4684–4693, 2010.
- [6] G. G. Zhanel, H. J. Adam, M. Baxter et al., *Antimicrobial Susceptibility of 42,938 Pathogens Isolated from Patients in Canadian Hospitals. CANWARD Study 2007–2016*, American Society for Microbiology (ASM) Microbe, New Orleans, LA, USA, 2017.
- [7] G. G. Zhanel, H. A. Adam, M. R. Baxter et al., "Antimicrobial susceptibility of 22,746 pathogens from Canadian hospitals: results of the CANWARD 2007–2011 study," *Journal of Antimicrobial Chemotherapy*, vol. 68, no. S1, pp. i7–i22, 2013.
- [8] A. Denisuk, P. R. S. Lagace-Wiens, J. D. Pitout et al., "Molecular epidemiology of extended-spectrum  $\beta$ -lactamase AmpC and carbapenemase producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from Canadian hospitals over a 5 year period: CANWARD 2007–2011," *Journal of Antimicrobial Chemotherapy*, vol. 68, no. S1, pp. i57–i65, 2013.
- [9] A. Denisuk, H. J. Adam, P. Lagace-Wiens et al., *A Decade of Extended-Spectrum  $\beta$ -Lactamase Producing Escherichia coli Surveillance Demonstrates Significant Increases In Prevalence: Results of the CANWARD Study 2007–2016*, American Society for Microbiology (ASM) Microbe, New Orleans, LA, USA, 2017.
- [10] K. A. Nichol, H. J. Adam, D. L. Roscoe et al., "Changing epidemiology of CMRSA10 (USA300) community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) in Canada," *Journal of Antimicrobial Chemotherapy*, vol. 68, no. S1, pp. i47–i55, 2013.
- [11] T. Simmer, H. Adam, M. Baxter et al., "Vancomycin-resistant enterococci (VRE) in Canadian hospitals: CANWARD 2007–2013," in *Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)*, Washington, DC, USA, September 2014.
- [12] A. Walkty, J. A. Karlowky, H. Adam et al., "In vitro activity of ceftolozane-tazobactam versus *Pseudomonas aeruginosa* isolates obtained from patients in Canadian hospitals," *Antimicrobial Agents and Chemotherapy*, vol. 57, no. 11, pp. 5707–5709, 2013.
- [13] M. Popovic, D. Steinort, S. Pillai, and C. Joukhadar, "Fosfomycin: an old, new friend?," *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 29, no. 2, pp. 127–142, 2010.
- [14] Monurol Sachet, *Package Insert*, Paladin Labs Inc., Saint-Laurent, QC, USA, 2017.
- [15] M. E. Falagas, K. P. Giannopoulou, G. N. Kokolakis, and P. I. Rafailidis, "Fosfomycin: use beyond urinary tract and gastrointestinal infections," *Clinical Infectious Diseases*, vol. 46, no. 7, pp. 1069–1077, 2008.
- [16] D. E. Karageorgopoulos, R. Wang, X. H. Yu, and M. E. Falagas, "Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens," *Journal of Antimicrobial Chemotherapy*, vol. 67, no. 2, pp. 255–268, 2012.
- [17] N. Roussos, D. E. Karageorgopoulos, G. Samonis, and M. E. Falagas, "Clinical significance of the pharmacokinetic and pharmacodynamics characteristics of fosfomycin for the treatment of patients with systemic infections," *International Journal of Antimicrobial Agents*, vol. 34, no. 6, pp. 506–515, 2009.
- [18] F. Gudiol, "Facts and myths about fosfomycin," *International Journal of Antimicrobial Agents*, vol. 29, no. S2, pp. S12–S13, 2007.
- [19] M. Trautmann, C. Meincke, K. Vogt, M. Ruhnke, and A. M. Lajous-Petter, "Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics," *Infection*, vol. 20, no. 6, pp. 350–354, 1992.
- [20] F. Shen, X. Tang, W. Cheng et al., "Fosfomycin enhances phagocytosis mediated killing of *Staphylococcus aureus* by extracellular traps and reactive oxygen species," *Scientific Reports*, vol. 18, no. 1, 2016.
- [21] Fomicyt, 2017, <https://www.medicines.org.uk/emc/medicine/28971>.
- [22] F. M. Kahan, J. S. Kahan, P. J. Cassidy, and H. Kropp, "The mechanism of action of fosfomycin (phosphonomycin)," *Annals of the New York Academy of Sciences*, vol. 235, no. 1, pp. 364–386, 1974.
- [23] B. Pfausler, H. Spiss, P. Dittrich et al., "Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis,"

- Journal of Antimicrobial Chemotherapy*, vol. 53, no. 5, pp. 848–852, 2004.
- [24] A. J. Lepak, M. Zhao, B. VanScoy et al., “In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*,” *Antimicrobial Agents and Chemotherapy*, vol. 61, no. 6, article e00476, 2017.
- [25] T. Mikuniya, Y. Kato, T. Ida et al., “Treatment of *Pseudomonas aeruginosa* biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model,” *Journal of Infection and Chemotherapy*, vol. 13, no. 5, pp. 285–290, 2007.
- [26] C. Marquès, J. Tasse, A. Pracros et al., “Effects of antibiotics on biofilm and unattached cells of a clinical *Staphylococcus aureus* isolate from bone and joint infection,” *Journal of Medical Microbiology*, vol. 64, no. 9, pp. 1021–1026, 2015.
- [27] S. Corvec, U. Furustrand Tafin, B. Betrisey, O. Borens, and A. Trampuz, “Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* in a foreign-body infection model,” *Antimicrobial Agents and Chemotherapy*, vol. 57, no. 3, pp. 1421–1427, 2013.
- [28] R. Mihailescu, U. Furustrand Tafin, S. Corvec et al., “High activity of fosfomycin and rifampin against methicillin-resistant *Staphylococcus aureus* biofilm in vitro and in an experimental foreign-body infection model,” *Antimicrobial Agents and Chemotherapy*, vol. 58, no. 5, pp. 2547–2553, 2014.
- [29] I. M. E. Falagas, E. K. Vouloumanou, G. Samonis, and K. Z. Vardakas, “Fosfomycin,” *Clinical Microbiology Reviews*, vol. 29, no. 2, pp. 321–347, 2016.
- [30] Clinical and Laboratory Standards Institute (CLSI), *M100 Performance Standards for Antimicrobial Susceptibility Testing*, Clinical and Laboratory Standards Institute, Wayne, PA, USA, 27th edition, 2017.
- [31] European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2017, <http://www.eucast.org>.
- [32] A. L. Barry and P. C. Fuchs, “In vitro susceptibility testing procedures for fosfomycin trometamol,” *Antimicrobial Agents and Chemotherapy*, vol. 35, no. 6, pp. 1235–1238, 1991.
- [33] A. L. Barry and S. D. Brown, “Antibacterial spectrum of fosfomycin trometamol,” *Journal of Antimicrobial Chemotherapy*, vol. 35, no. 1, pp. 228–230, 1995.
- [34] R. K. Flamm, D. Shortridge, P. R. Rhomberg et al., *Fosfomycin Activity When Tested against Gram-Positive and Gram-Negative US Isolates Collected by the SENTRY Antimicrobial Surveillance Program*, Microbe, New Orleans, LA, USA, 2017.
- [35] J. A. Karlowsky, A. J. Denisuk, P. R. S. Lagace-Wiens et al., “In vitro activity of fosfomycin against *Escherichia coli* isolated from patients with urinary infections in Canada as part of the CANWARD surveillance study,” *Antimicrobial Agents and Chemotherapy*, vol. 58, no. 2, pp. 1252–1256, 2014.
- [36] A. Endimiani, G. Patel, K. M. Hujer et al., “In vitro activity of fosfomycin against *bla*<sub>KPC</sub>-containing *Klebsiella pneumoniae* isolates, including those nonsusceptible to tigecycline and/or colistin,” *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 1, pp. 526–529, 2010.
- [37] M. Kaase, F. Szabados, A. Anders, and S. G. Gatermann, “Fosfomycin susceptibility in carbapenem-resistant *Enterobacteriaceae* from Germany,” *Journal of Clinical Microbiology*, vol. 52, no. 6, pp. 1893–1897, 2014.
- [38] P.-L. Ho, J. Chan, W.-U. Lo et al., “Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary *Escherichia coli* isolates,” *Journal of Medical Microbiology*, vol. 62, no. 11, pp. 1707–1713, 2013.
- [39] J. Navas, J. León, M. Arroyo, and J. M. García Lobo, “Nucleotide sequence and intracellular location of the product of the fosfomycin resistance gene from transposon Tn2921,” *Antimicrobial Agents and Chemotherapy*, vol. 34, no. 10, pp. 2016–2018, 1990.
- [40] R. Rigsby, K. Fillgrove, L. Beihoffer, and R. Armstrong, “Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily,” *Methods in Enzymology*, vol. 401, pp. 367–379, 2005.
- [41] A. Castaneda-Garcia, J. Blazquez, and A. Rodriguez-Rojas, “Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance,” *Antibiotics*, vol. 2, no. 2, pp. 217–236, 2013.
- [42] L. L. Silver, “Fosfomycin: mechanism and resistance,” *Cold Spring Harbor Perspectives in Medicine*, vol. 7, no. 2, article a025262, 2017.
- [43] S. V. Sharma, V. K. Jothivasan, G. L. Newton et al., “Chemical and chemoenzymatic syntheses of bacillithiol: a unique low-molecular-weight thiol amongst low G + C Gram-positive bacteria,” *Angewandte Chemie International Edition*, vol. 50, no. 31, pp. 7101–7104, 2011.
- [44] A. A. Roberts, S. V. Sharma, A. W. Strankman et al., “Mechanistic studies of FosB: a divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in *Staphylococcus aureus*,” *Biochemical Journal*, vol. 451, no. 1, pp. 69–79, 2013.
- [45] P. García, P. Arca, and J. Evaristo Suárez, “Product of fosC, a gene from *Pseudomonas syringae*, mediates fosfomycin resistance by using ATP as cosubstrate,” *Antimicrobial Agents and Chemotherapy*, vol. 39, no. 7, pp. 1569–1573, 1995.
- [46] J. Oteo, B. Orden, V. Bautista et al., “CTX-M-15-producing urinary *Escherichia coli* O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin,” *Journal of Antimicrobial Chemotherapy*, vol. 64, no. 4, pp. 712–717, 2009.
- [47] J. Oteo, V. Bautista, N. Lara et al., “Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase-producing *Escherichia coli*,” *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 11, pp. 2459–2463, 2010.
- [48] G. C. Schito, K. G. Naber, H. Botto et al., “The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections,” *International Journal of Antimicrobial Agents*, vol. 34, no. 5, pp. 407–413, 2009.
- [49] B. Grabein, W. Graninger, J. R. Baño, A. Dinh, and D. B. Liesenfeld, “Intravenous fosfomycin—back to the future. Systemic review and meta-analysis of the clinical literature,” *Clinical Microbiology and Infection*, vol. 23, no. 6, pp. 363–372, 2017.
- [50] A. L. Nilsson, O. G. Berg, O. Aspevall, G. Kahlmeter, and D. I. Andersson, “Biological costs and mechanisms of fosfomycin resistance in *Escherichia coli*,” *Antimicrobial Agents and Chemotherapy*, vol. 47, no. 9, pp. 2850–2858, 2003.
- [51] K. S. Kaye, L. B. Rice, A. Dane et al., “Intravenous fosfomycin (ZTI-01) for the treatment of complicated urinary tract infections (cUTI) including acute pyelonephritis (AP): results from a multi-center, randomized, double-blind phase 2/3 study in hospitalized adults (ZEUS),” *Open Forum Infectious Diseases*, vol. 4, no. S1, p. S528, 2017.
- [52] M. E. Falagas, A. C. Kastoris, D. E. Karageorgopoulos, and P. I. Rafailidis, “Fosfomycin for the treatment of infections

- caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systemic review of microbiological, animal and clinical studies," *International Journal of Antimicrobial Agents*, vol. 34, no. 2, pp. 111–120, 2009.
- [53] A. Dinh, J. Salomon, J. P. Bru, and L. Bernard, "Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria," *Scandinavian Journal of Infectious Diseases*, vol. 44, no. 3, pp. 182–189, 2012.
- [54] M. E. Falagas, A. C. Kastoris, A. M. Kapaskelis, and D. E. Karageorgopoulos, "Karageorgopoulos. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum  $\beta$ -lactamase producing, *Enterobacteriaceae* infections: a systemic review," *The Lancet Infectious Diseases*, vol. 10, no. 1, pp. 43–50, 2010.
- [55] D. Baron, M. D. Touze, F. Tasseau, A. Reynaud, M. Derriennic, and A. L. Courtieu, "Comparison of fosfomycin-penicillin M and penicillin M-gentamicin: apropos of 35 severe infections caused by methicillin-susceptible *Staphylococcus aureus*," *La Revue de Médecine Interne*, vol. 8, no. 1, pp. 109–114, 1987.
- [56] L. R. Nissen, J. Jacobsen, T. J. Ravn, C. Wahlgreen, and H. Auning-Hansen, "Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia," *Infection*, vol. 14, no. 5, pp. 246–249, 1986.
- [57] L. Andakar, L. G. Burman, A. Eklund et al., "Fosfomycin/metronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective colorectal surgery: a randomized double-blind multicenter trial in 517 patients," *European Journal of Surgery*, vol. 158, no. 3, pp. 181–185, 1992.
- [58] M. Nohr, J. C. Andersen, and K. E. Juul-Jensen, "Prophylactic single-dose fosfomycin and metronidazole compared with neomycin, bacitracin, metronidazole and ampicillin in elective colorectal operations," *Acta Chirurgica Scandinavica*, vol. 156, no. 3, pp. 223–230, 1990.
- [59] J. P. Bedirdjian, J. P. Morin, B. Fouchet, and J. P. Fillastre, "Effect of fosfomycin on respiration by rat kidney mitochondria," *Drugs Under Experimental and Clinical Research*, vol. 4, pp. 57–62, 1978.
- [60] E. A. Neuner, J. Sekeres, G. S. Hall, and D. van Duin, "Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms," *Antimicrobial Agents and Chemotherapy*, vol. 56, no. 11, pp. 5744–5748, 2012.
- [61] Y. Cai, R. Fan, M. Wang, M. M. An, and B. B. Liang, "Synergistic effects of aminoglycosides and fosfomycin on *Pseudomonas aeruginosa* *in vitro* and biofilm infections in a rat model," *Journal of Antimicrobial Chemotherapy*, vol. 64, no. 3, pp. 563–566, 2009.
- [62] M. V. Schintler, F. Traunmuller, J. Metzler et al., "High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection," *Journal of Antimicrobial Chemotherapy*, vol. 64, no. 3, pp. 574–578, 2009.
- [63] F. J. Legat, A. Maier, P. Dittrich et al., "Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome," *Antimicrobial Agents and Chemotherapy*, vol. 47, no. 1, pp. 371–374, 2003.
- [64] C. Joukhadar, N. Klein, P. Dittrich et al., "Target site penetration of fosfomycin in critically ill patients," *Journal of Antimicrobial Chemotherapy*, vol. 51, no. 5, pp. 1247–1252, 2003.
- [65] E. Farago, I. J. Kiss, and Z. Nabradi, "Serum and lung tissue levels of fosfomycin in humans," *International Journal of Clinical Pharmacology, Therapy, and Toxicology*, vol. 18, pp. 554–558, 1980.
- [66] V. Matzi, J. Lindenmann, C. Porubsky et al., "Extracellular concentration of fosfomycin in lung tissue of septic patients," *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 5, pp. 995–998, 2010.
- [67] J. A. Reguera, F. Baquero, J. Berenguer, M. Martinez-Ferrer, and J. L. Martinez, "Beta-lactam-fosfomycin antagonism involving modification of penicillin-binding protein 3 in *Pseudomonas aeruginosa*," *Antimicrobial Agents and Chemotherapy*, vol. 34, no. 11, pp. 2093–2096, 1990.
- [68] D. Fries, L. Jacques, D. Mathieu, and N. Hardy, "Interet de la fosfomycine dans le traitement des forms severes de pyelonephritis," *Médecine et Maladies Infectieuses*, vol. 11, no. 7, pp. 425–429, 1981.
- [69] G. Habib, P. Lancellotti, M. J. Antunes et al., "2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)," *European Heart Journal*, vol. 36, no. 44, pp. 3075–3128, 2015.
- [70] A. Del Rio, O. Gasch, A. Moreno et al., "Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant *Staphylococcus aureus*: a multicenter clinical trial," *Clinical Infectious Diseases*, vol. 59, no. 8, pp. 1105–1112, 2014.
- [71] H. B. Drugeon and A. Kazmierczak, "Les associations avec la fosfomycine sur *Staphylococcus*: les partenaires les plus interessants," *La Semaine Des Hopitaux De Paris*, vol. 63, pp. 3549–3552, 1987.
- [72] D. Baron, H. Drugeon, A. L. Courtieu, and F. Nicolas, "Septicemies et infections graves a germes multiresistants. Resultats du traitement par la fosfomycine," *Médecine et Maladies Infectieuses*, vol. 11, no. 4, pp. 255–261, 1981.
- [73] J. B. Dureux, P. H. Canton, M. Weber, P. Toussain, and G. Roche, "La fosfomycine dans le traitement des etats septicemiques et des endocarditis bacteriennes," *Médecine et Maladies Infectieuses*, vol. 11, no. 10, pp. 524–532, 1981.
- [74] M. Wolf, "Place de la fosfomycine dans le traitement des infections a *Pseudomonas aeruginosa*," *La Semaine Des Hopitaux De Paris*, vol. 63, pp. 3570–3572, 1987.
- [75] A. Meißner, R. Rahmzadeh, and R. Haag, "Adjuvant fosfomycin medication in chronic osteomyelitis," *Infection*, vol. 17, no. 3, pp. 146–151, 1989.
- [76] D. Stengel, E. Gorzer, M. Schintler et al., "Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin," *Journal of Chemotherapy*, vol. 17, no. 5, pp. 527–535, 2005.
- [77] A. J. Pan, Q. Mei, Y. Ye, H. R. Li, B. Liu, and J. B. Li, "Validation of the mutant selection window hypothesis with fosfomycin against *Escherichia coli* and *Pseudomonas aeruginosa*: an *in vitro* and *in vivo* comparative study," *Journal of Antibiotics*, vol. 70, no. 2, pp. 166–173, 2017.



**Hindawi**

Submit your manuscripts at  
[www.hindawi.com](http://www.hindawi.com)

